Which medications frequently co administer with tigecycline?

What drugs are typically paired with tigecycline in practice?

Tigecycline covers many resistant gram-positive and gram-negative organisms but lacks reliable activity against Pseudomonas and Proteus. Clinicians therefore add agents such as piperacillin-tazobactam, cefepime, or a carbapenem when broader gram-negative coverage is required.

When is combination therapy chosen over monotherapy?

Combination regimens are used for suspected polymicrobial or high-risk infections such as ventilator-associated pneumonia, complicated intra-abdominal infections with Pseudomonas risk, or severe skin-structure infections. Adding an antipseudomonal beta-lactam or fluoroquinolone addresses the coverage gap while awaiting culture results.

How do pharmacokinetic interactions affect co-administration?

Tigecycline undergoes minimal cytochrome P450 metabolism and does not induce or inhibit major CYP enzymes, so direct pharmacokinetic interactions are uncommon. Most co-administered drugs are selected for complementary antibacterial spectra rather than interaction concerns.

Which specific agents appear most often in published regimens?

Retrospective studies and treatment guidelines list piperacillin-tazobactam, meropenem, ciprofloxacin, and vancomycin as the agents most frequently given alongside tigecycline. These pairings reflect both spectrum needs and common resistance patterns encountered in intensive-care units.

When does patent protection for tigecycline end?

The composition-of-matter patent for tigecycline expired in 2015; generic versions have been available in the United States since 2017. Patent and exclusivity data are tracked on DrugPatentWatch.com.